Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect



CAS Number: 1231929-97-7

Therapeutic Category
Anti-Cancer/ Oncology
API Technology
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Innovator Brand (USA)

Mechanism of Action

Abemaciclib is a type of drug called a selective cyclin-dependent kinase (CDK) inhibitor. It specifically targets and inhibits the activity of CDK4 and CDK6, two proteins that play a critical role in regulating cell division.

In cancer cells, the uncontrolled proliferation of cells is often driven by elevated activity of CDK4 and CDK6. By inhibiting these proteins, Abemaciclib can disrupt the cell cycle and prevent the uncontrolled division of cancer cells. This can lead to cell death and slow down the growth of tumors.

Abemaciclib is used to treat certain types of breast cancer that have spread to other parts of the body (metastatic) and have a specific genetic change (positive for human epidermal growth factor receptor 2 (HER2) or estrogen receptor (ER)/progesterone receptor (PR) positive). It is used in combination with other cancer treatments, such as hormonal therapy, to help control the cancer and slow down its progression.


Abemaciclib is a medication that belongs to the class of drugs known as CDK4/6 inhibitors, and is indicated for the treatment of certain types of cancer. The following are the specific indications for abemaciclib:

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer: Abemaciclib is used in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.

HR-positive, HER2-negative breast cancer: Abemaciclib is used in combination with fulvestrant for the treatment of HR-positive, HER2-negative breast cancer in women who have gone through menopause and whose cancer has progressed after treatment with endocrine therapy.

It is important to note that the use of abemaciclib should be guided by the recommendations of a healthcare provider who is familiar with the patient's medical history and current condition.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Abemaciclib API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Abemaciclib API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.

Oncology API Products:

Learn More

Contact Us

Please fill in the following form for API Requirement & we'll get back to you shortly

We are here to help, if you have any country specific requirements.


No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.